Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more
Lasa Supergenerics Limited (LASA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.005x
Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has a cash flow conversion efficiency ratio of 0.005x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹2.59 Million) by net assets (₹563.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lasa Supergenerics Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lasa Supergenerics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lasa Supergenerics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Venerable Ventures Ltd
V:VLV
|
-3.164x |
|
WINDELN.DE SE INH O.N.
F:WDL1
|
N/A |
|
PT Trimuda Nuansa Citra Tbk
JK:TNCA
|
0.001x |
|
Bless Asset Group PCL
BK:BLESS
|
0.018x |
|
Canadian Metals Inc
PINK:CNMTF
|
-0.013x |
|
NETUM GROUP OYJ
F:79J
|
N/A |
|
Pacte Novation
PA:MLPAC
|
N/A |
|
BULGOLD Inc.
V:ZLTO
|
N/A |
Annual Cash Flow Conversion Efficiency for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lasa Supergenerics Limited from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹837.13 Million | ₹-28.24 Million | -0.034x | -252.47% |
| 2024-03-31 | ₹966.76 Million | ₹21.39 Million | 0.022x | +115.13% |
| 2023-03-31 | ₹1.18 Billion | ₹-173.00 Million | -0.146x | -350.68% |
| 2022-03-31 | ₹1.58 Billion | ₹92.12 Million | 0.058x | -77.56% |
| 2021-03-31 | ₹1.59 Billion | ₹413.10 Million | 0.260x | +169.95% |
| 2020-03-31 | ₹1.41 Billion | ₹136.23 Million | 0.096x | -75.06% |
| 2019-03-31 | ₹1.05 Billion | ₹406.58 Million | 0.386x | +12.48% |
| 2018-03-31 | ₹1.17 Billion | ₹402.80 Million | 0.343x | +962.97% |
| 2017-03-31 | ₹754.94 Million | ₹-30.03 Million | -0.040x | -- |